Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riociguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 known ✓ | Q02108 | 11/20 | 0.60 |
| ▸ | GUCY1B1 known ✓ | Q02153 | 11/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riociguat SCHEMBL29419573 | 1.00 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL245457 | 1.00 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29357210 | 1.00 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL15744746 | 0.94 | KCNH2 (0.89) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL31037564 | 0.94 | KCNH2 (0.88) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12593410 | 0.92 | KCNH2 (0.86) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL12364300 | 0.92 | KCNH2 (0.84) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5477000 | 0.92 | KCNH2 (0.84) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL256202 | 0.91 | KCNH2 (0.84) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL31037565 | 0.91 | KCNH2 (0.83) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2025122074-A1 | LOW DOSE RIOCIGUAT COMPOSITIONS | SANTA FARMA ILAC SANAYII A.S. (TR) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025122075-A1 | PHARMACEUTICAL COMPOSITIONS OF RIOCIGUAT | SANTA FARMA ILAC SANAYII A.S. (TR) | 2025-06-12 | — | — | WO | disclosed |
| EP-4456896-A1 | TREATMENT OF CARDIOPULMONARY DISORDERS | Bayer Aktiengesellschaft (DE) | 2024-11-06 | — | — | EP | disclosed |
| EP-4456871-A1 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | Bayer Aktiengesellschaft (DE) | 2024-11-06 | — | — | EP | disclosed |
| WO-2024165966-A1 | GASTRORETENTIVE EXTENDED RELEASE COMPOSITIONS OF RIOCIGUAT | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-08-15 | — | — | WO | disclosed |
| WO-2023126438-A1 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126437-A1 | TREATMENT OF CARDIOPULMONARY DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-06 | — | — | WO | disclosed |
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | disclosed |
| WO-2022147183-A1 | PHARMACEUTICAL EXTENDED RELEASE SUSPENSIONS OF RIOCIGUAT | Jubilant Pharma Holdings Inc. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022144930-A1 | PHARMACEUTICAL ORAL SUSPENSIONS OF RIOCIGUAT | Jubilant Generics Limited (IN) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022144919-A1 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF RIOCIGUAT | JUBILANT GENERICS LTD (IN) | 2022-07-07 | — | — | WO | disclosed |
| CN-110946826-B | Riociguat oral preparation and preparation method thereof | 烟台大学 | 2022-02-22 | — | — | CN | disclosed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | disclosed |